Apixaban versus enoxaparin in patients with total knee arthroplasty: A meta-analysis of randomised trials

Thrombosis and Haemostasis

Volumn 105, Issue 2, 2011, Pages 245-253

  Huang, Jiahao ^a   Cao, Yunfei ^a   Liao, Cun ^a   Wu, Liucheng ^a   Gao, Feng ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Apixaban; Enoxaparin; Meta analysis; Total knee arthroplasty

Indexed keywords

APIXABAN; ENOXAPARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG SAFETY; HEART INFARCTION; HUMAN; LUNG EMBOLISM; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; ENOXAPARIN; EVIDENCE-BASED MEDICINE; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; ODDS RATIO; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 79851483966     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-08-0552     Document Type: Article

References (14)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
2. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101: 77-85.
3. He K, He B, Grace JE et al. Preclinical pharmacokinetics and metabolism of apixaban, a potent and selective factor Xa inhibitor. Blood 2006; 108: 273a (Abstract 910).
4. Jiang X, Crain EJ, Luettgen JM, et al.Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 2009; 101: 780-782.
5. Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010; 103: 62-70.
6. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008.
7. The European Agency for the Evaluation of Medicinal Products, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. Available at: http: //www.emea.europa.eu/pdfs/human/ewp/ 70798en-fin.pdf. Accessed Dec 1, 2009.
8. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
9. Sutton AJ, Abrams KR. Methods for meta-analysis in medical research. Wiley, Chichester, 2000.
10. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634. (Pubitemid 27387172)
11. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
12. Moher D, Cook DJ, Eastwood S et al. Improving the quality of reports of metaanalyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-1900.
13. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
14. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-2375. (Pubitemid 350154345)